Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Integrating pharmacogenomics into drug development.

Ann E Ferentz1

  • 1Variagenics, Inc., 60 Hampshire Street, Cambridge, MA 02139-1548, USA. aferentz@variagenics.com

Pharmacogenomics
|August 8, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A model for the structure of the Escherichia coli SOS-regulated UmuD2 protein.

DNA repair·2003
Same author

Variagenics, inc.

Pharmacogenomics·2002
Same journal

Closely similar tacrolimus morning troughs and graft function across the recipients' common <i>ABCB1</i> polymorphisms (<i>c.2677G>T/A</i>, <i>c.1236C>T</i>, <i>c.3435C>T</i>) early after renal transplantation.

Pharmacogenomics·2026
Same journal

Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use.

Pharmacogenomics·2026
Same journal

Guidance from an informed public on collecting and sharing PGx test results for major depressive disorder: "It's no different from your blood type".

Pharmacogenomics·2026
Same journal

Optimizing pharmacogenomics workflows: a qualitative evaluation of clinical service delivery models.

Pharmacogenomics·2026
Same journal

Combinations of single gene predictors with AI-driven polygenic precision therapies in cardiovascular diseases.

Pharmacogenomics·2026
Same journal

Practical guide to implementing pre-emptive pharmacogenetic screening in routine pediatric oncology care.

Pharmacogenomics·2026
See all related articles

Pharmacogenetics links genetic variations to drug responses, enabling personalized medicine. This review explores using pharmacogenomic technologies to develop drugs and diagnostic tests for better patient outcomes.

Area of Science:

  • Pharmacology
  • Genetics
  • Molecular Biology

Background:

  • Inherited differences in drug effects recognized in the 1950s established a genetic basis for drug response.
  • Advancements in genetics and molecular biology revealed associations between specific genetic variations (polymorphisms) and drug responses.
  • Polymorphisms influencing responses to diverse drugs, from analgesics to chemotherapeutics, are now well-documented.

Purpose of the Study:

  • To review the application of pharmacogenomic technologies in drug development.
  • To highlight the role of pharmacogenetics in creating predictive markers for drug response.
  • To discuss the integration of pharmacogenomic data for developing companion diagnostics.

Main Methods:

  • Literature review of pharmacogenetic studies and pharmacogenomic technologies.

Related Experiment Videos

  • Analysis of existing examples of polymorphisms affecting drug response.
  • Exploration of strategies for incorporating pharmacogenomics into the drug development pipeline.

    • Main Results:

    • Identification of numerous genetic polymorphisms impacting drug efficacy and toxicity.
    • Demonstration of pharmacogenomics' potential to predict individual drug responses.
    • Validation of pharmacogenomic approaches for guiding therapeutic decisions.

    Conclusions:

    • Pharmacogenetics is crucial for precision medicine, tailoring drug selection and dosage.
    • Pharmacogenomic technologies offer a pathway to optimize drug development and regulatory approval.
    • Integrating pharmacogenomics ensures the safe and effective use of medications through companion diagnostics.